{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:12:41Z","timestamp":1790482361979,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neoplasm development in Multiple Sclerosis (MS) patients treated with disease-modifying therapies (DMTs) has been widely discussed. The aim of this work is to determine neoplasm frequency, relationship with the prescription pattern of DMTs, and influence of the patients\u2019 baseline characteristics. Data from 250 MS outpatients were collected during the period 1981\u20132019 from the medical records of the Neurology Service of the HUPM (<jats:italic>Hospital Universitario Puerta del Mar<\/jats:italic>)\u2014in Southern Spain\u2014and analysed using Cox models. Neoplasm prevalence was 24%, mainly located on the skin, with cancer prevalence\u00a0as expected for MS (6.8%). Latency period from MS onset to neoplasm diagnosis was 10.4\u2009\u00b1\u20096.9\u00a0years (median 9.30 [0.9\u201330.5]). During the observation period \u03b2-IFN (70.4% of patients), glatiramer acetate (30.4%), natalizumab (16.8%), fingolimod (24.8%), dimethyl fumarate (24.0%), alemtuzumab (6.0%), and teriflunomide (4.8%) were administered as monotherapy. Change of pattern in step therapy was significantly different in cancer patients vs unaffected individuals (<jats:italic>p<\/jats:italic>\u2009=\u20090.011) (29.4% did not receive DMTs [<jats:italic>p<\/jats:italic>\u2009=\u20090.000]). Extended Cox model: Smoking (HR\u2009=\u20093.938, CI 95% 1.392\u201311.140, <jats:italic>p<\/jats:italic>\u2009=\u20090.010), being female (HR\u2009=\u20092.006, 1.070\u20133.760, <jats:italic>p<\/jats:italic>\u2009=\u20090.030), and age at MS diagnosis (AGE-DG) (HR\u2009=\u20091.036, 1.012\u20131.061, <jats:italic>p<\/jats:italic>\u2009=\u20090.004) were risk factors for neoplasm development. Secondary progressive MS (SPMS) phenotype (HR\u2009=\u20090.179, 0.042\u20130.764, <jats:italic>p<\/jats:italic>\u2009=\u20090.020) and treatment-time with IFN (HR\u2009=\u20090.923, 0.873\u20130.977, <jats:italic>p<\/jats:italic>\u2009=\u20090.006) or DMF (HR\u2009=\u20090.725, 0.507\u20131.036, <jats:italic>p<\/jats:italic>\u2009=\u20090.077) were protective factors. Tobacco and IFN lost their negative\/positive influence as survival time increased. Cox PH model: Tobacco\/AGE-DG interaction was a risk factor for cancer (HR\u2009=\u20091.099, 1.001\u20131.208, <jats:italic>p<\/jats:italic>\u2009=\u20090.049), followed by FLM treatment-time (HR\u2009=\u20091.219, 0.979\u20131.517). In conclusion, smoking, female sex, and AGE-DG were risk factors, and SPMS and IFN treatment-time were protective factors for neoplasm development; smoking\/AGE-DG interaction was the main cancer risk factor.<\/jats:p>","DOI":"10.1038\/s41598-021-91912-x","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T10:04:25Z","timestamp":1623751465000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients"],"prefix":"10.1038","volume":"11","author":[{"given":"Rosal\u00eda","family":"Gil-Bernal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Gonz\u00e1lez-Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Espinosa-Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"G\u00f3mez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"issue":"8","key":"91912_CR1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1136\/jnnp-2016-315238","volume":"88","author":"HMB Lunde","year":"2017","unstructured":"Lunde, H. M. B. et al. Survival and cause of death in multiple sclerosis: A 60-year longitudinal population study. J. Neurol. Neurosurg. Psychiatry 88(8), 621\u2013625 (2017).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"91912_CR2","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1007\/s00415-014-7370-3","volume":"261","author":"SS Jick","year":"2014","unstructured":"Jick, S. S. et al. Mortality of patients with multiple sclerosis: A cohort study in UK primary care. J. Neurol. 261, 1508\u20131517 (2014).","journal-title":"J. Neurol."},{"key":"91912_CR3","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/brain\/awh104","volume":"127","author":"H Br\u00f9nnum-Hansen","year":"2004","unstructured":"Br\u00f9nnum-Hansen, H., Koch-Henriksen, N. & Stenager, E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 127, 844\u2013850 (2004).","journal-title":"Brain"},{"key":"91912_CR4","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.3389\/fimmu.2019.02954","volume":"10","author":"E Melamed","year":"2020","unstructured":"Melamed, E. & Lee, M. W. Multiple sclerosis and cancer: The Ying-Yang effect of disease modifying therapies. Front. Immunol. 10, 2954. https:\/\/doi.org\/10.3389\/fimmu.2019.02954 (2020).","journal-title":"Front. Immunol."},{"issue":"9","key":"91912_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40263-015-0277-4","volume":"29","author":"AM Subei","year":"2015","unstructured":"Subei, A. M. & Ontaneda, D. Risk mitigation strategies for adverse reactions associated with the disease modifying drugs in multiple sclerosis. CNS Drugs 29(9), 759\u2013771 (2015).","journal-title":"CNS Drugs"},{"key":"91912_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1468-1331.2012.03668.x","volume":"19","author":"A Lalmohamed","year":"2012","unstructured":"Lalmohamed, A. et al. Causes of death in patients with multiple sclerosis and matched referent subjects: A population-based cohort study. Eur. J. Neurol. 19, 1007\u20131014 (2012).","journal-title":"Eur. J. Neurol."},{"key":"91912_CR7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s40263-018-0564-y","volume":"32","author":"C Lebrun","year":"2018","unstructured":"Lebrun, C. & Rocher, F. Cancer risk in patients with multiple sclerosis: Potential impact of disease-modifying drugs. CNS Drugs 32, 939\u2013949 (2018).","journal-title":"CNS Drugs"},{"key":"91912_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.critrevonc.2015.10.002","volume":"98","author":"AP Kyritsis","year":"2016","unstructured":"Kyritsis, A. P., Boussios, S. & Pavlidis, N. Cancer specific risk in multiple sclerosis patients. Crit Rev Oncol \/ Hematol 98, 29\u201334 (2016).","journal-title":"Crit Rev Oncol \/ Hematol"},{"key":"91912_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.msard.2019.08.005","volume":"35","author":"K Hongell","year":"2019","unstructured":"Hongell, K. et al. Risk of cancer among Finnish multiple sclerosis patients. Mult. Scler. Relat. Disord 35, 221\u2013227 (2019).","journal-title":"Mult. Scler. Relat. Disord"},{"issue":"11","key":"91912_CR10","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","volume":"89","author":"E Havrdova","year":"2017","unstructured":"Havrdova, E. et al. Alemtuzumab CARE-MS I 5-year follow-up durable efficacy in the absence of continuous MS therapy. Neurology 89(11), 1107\u20131116 (2017).","journal-title":"Neurology"},{"key":"91912_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/0-387-29150-4","volume-title":"Survival Analysis: A Self-Learning Text","author":"DG Kleinbaum","year":"2005","unstructured":"Kleinbaum, D. G. & Klein, M. Survival Analysis: A Self-Learning Text 2nd edn. (Springer, 2005).","edition":"2"},{"key":"91912_CR12","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer 49, 1374\u20131403 (2013).","journal-title":"Eur. J. Cancer"},{"key":"91912_CR13","volume-title":"Harrison. Principios de Medicina Interna","author":"D Kasper","year":"2016","unstructured":"Kasper, D. et al. Harrison. Principios de Medicina Interna Vol. 2 (McGraw-Hill, 2016)."},{"key":"91912_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejogrb.2018.05.026","volume":"226","author":"J Monleon","year":"2018","unstructured":"Monleon, J. et al. Epidemiology of uterine myomas and clinical practice in Spain: An observational study. Eur. J. Obstet. Gynecol. Reprod. Biol. 226, 59\u201365 (2018).","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"4","key":"91912_CR15","first-page":"127","volume":"2","author":"AR Zadeh","year":"2015","unstructured":"Zadeh, A. R. et al. Prevalence of benign tumors among patients with multiple sclerosis. Am. J. Exp. Clin. Res. 2(4), 127\u2013132 (2015).","journal-title":"Am. J. Exp. Clin. Res."},{"issue":"11","key":"91912_CR16","doi-asserted-by":"publisher","first-page":"e0188120","DOI":"10.1371\/journal.pone.0188120","volume":"12","author":"X Moisset","year":"2017","unstructured":"Moisset, X. et al. Decreased prevalence of cancer in patients with multiple sclerosis: A case\u2013control study. PLoS ONE 12(11), e0188120 (2017).","journal-title":"PLoS ONE"},{"issue":"4","key":"91912_CR17","first-page":"1119","volume":"32","author":"AL Franks","year":"2012","unstructured":"Franks, A. L. & Slansky, J. E. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res. 32(4), 1119\u20131136 (2012).","journal-title":"Anticancer Res."},{"key":"91912_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ejim.2015.02.016","volume":"26","author":"MJ Forjaz","year":"2015","unstructured":"Forjaz, M. J. et al. Chronic conditions, disability, and quality of life in older adults with multimorbidity in Spain. Eur. J. Intern. Med. 26, 176\u2013181 (2015).","journal-title":"Eur. J. Intern. Med."},{"issue":"1","key":"91912_CR19","doi-asserted-by":"publisher","first-page":"e0169426","DOI":"10.1371\/journal.pone.0169426","volume":"12","author":"FB Larsen","year":"2017","unstructured":"Larsen, F. B. et al. A latent class analysis of multimorbidity and the relationship to socio-demographic factors and health-related quality of life. A national population-based study of 162,283 Danish adults. PLoS ONE 12(1), e0169426 (2017).","journal-title":"PLoS ONE"},{"issue":"3","key":"91912_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/1352458514564489","volume":"21","author":"RA Marrie","year":"2015","unstructured":"Marrie, R. A. et al. A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Mult. Scler. J. 21(3), 294\u2013304 (2015).","journal-title":"Mult. Scler. J."},{"issue":"7","key":"91912_CR21","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/cam4.1098","volume":"6","author":"RA Sabol","year":"2017","unstructured":"Sabol, R. A. et al. Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR). Cancer Med. 6(7), 1541\u20131551 (2017).","journal-title":"Cancer Med."},{"issue":"1","key":"91912_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-017-0932-0","volume":"17","author":"P Ragonese","year":"2017","unstructured":"Ragonese, P. et al. Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study. BMC Neurol. 17(1), 1\u20136 (2017).","journal-title":"BMC Neurol."},{"issue":"1","key":"91912_CR23","doi-asserted-by":"publisher","first-page":"100926","DOI":"10.1016\/j.tranon.2020.100926","volume":"14","author":"T Rupp","year":"2021","unstructured":"Rupp, T. et al. Terapeutic potential of Fingolimod in triple negative breast cancer preclinical models. Transl Oncol 14(1), 100926 (2021).","journal-title":"Transl Oncol"},{"key":"91912_CR24","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1007\/s40265-020-01422-9","volume":"80","author":"K Rammohan","year":"2020","unstructured":"Rammohan, K. et al. The development of cladribine tablets for the treatment of multiple sclerosis: A comprehensive review. Drugs 80, 1901\u20131928 (2020).","journal-title":"Drugs"},{"key":"91912_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10549-004-2229-4","volume":"89","author":"A Achiron","year":"2005","unstructured":"Achiron, A. et al. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res. Treat. 89, 265\u2013270 (2005).","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"91912_CR26","first-page":"95","volume":"11","author":"AR Zadeh","year":"2019","unstructured":"Zadeh, A. R. et al. Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1. Int. J. Physiol. Pathophysiol. Pharmacol. 11(4), 95\u2013104 (2019).","journal-title":"Int. J. Physiol. Pathophysiol. Pharmacol."},{"issue":"4","key":"91912_CR27","first-page":"105","volume":"11","author":"AR Zadeh","year":"2019","unstructured":"Zadeh, A. R. et al. Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2. Int. J. Physiol. Pathophysiol. Pharmacol. 11(4), 105\u2013114 (2019).","journal-title":"Int. J. Physiol. Pathophysiol. Pharmacol."},{"issue":"3","key":"91912_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00701-016-3019-6","volume":"159","author":"L Galloway","year":"2017","unstructured":"Galloway, L., Vakili, N. & Spears, J. Spontaneous regression of a parafalcine meningioma in a multiple sclerosis patient being treated with interferon beta-1a. Acta Neurochir. 159(3), 469\u2013471 (2017).","journal-title":"Acta Neurochir."},{"key":"91912_CR29","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/brain\/awz055","volume":"142","author":"E Kingwell","year":"2019","unstructured":"Kingwell, E. et al. Multiple sclerosis: Effect of beta interferon treatment on survival. Brain 142, 1324\u20131333 (2019).","journal-title":"Brain"},{"key":"91912_CR30","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1007\/s00415-020-09848-7","volume":"267","author":"J Sabin","year":"2020","unstructured":"Sabin, J. et al. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: A prospective observational multicenter study in a real-life Spanish population. J. Neurol. 267, 2362\u20132371 (2020).","journal-title":"J. Neurol."},{"issue":"5","key":"91912_CR31","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ana.25701","volume":"87","author":"P Alping","year":"2020","unstructured":"Alping, P. et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann. Neurol. 87(5), 688\u2013699 (2020).","journal-title":"Ann. Neurol."},{"key":"91912_CR32","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1093\/brain\/aws148","volume":"135","author":"E Kingwell","year":"2012","unstructured":"Kingwell, E. et al. Cancer risk in multiple sclerosis: Findings from British Columbia, Canada. Brain 135, 2973\u20132979 (2012).","journal-title":"Brain"},{"key":"91912_CR33","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1191\/1352458504ms1026oa","volume":"10","author":"R Hohlfeld","year":"2004","unstructured":"Hohlfeld, R. Immunologic factors in primary progressive multiple sclerosis. Mult. Scler. 10, S16\u2013S22 (2004).","journal-title":"Mult. Scler."},{"issue":"13","key":"91912_CR34","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1212\/01.wnl.0000345366.10455.62","volume":"72","author":"S Bahmanyar","year":"2009","unstructured":"Bahmanyar, S. et al. Cancer risk among patients with multiple sclerosis and their parents. Neurology 72(13), 1170\u20131177 (2009).","journal-title":"Neurology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91912-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91912-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91912-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T09:48:34Z","timestamp":1670060914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91912-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["91912"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-91912-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,15]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12533"}}